Revenue Breakdown
Composition ()
No data
Revenue Streams
Genmab A/S (GMAB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Royalties, accounting for 82.3% of total sales, equivalent to $841.00M. Other significant revenue streams include Net product sales and Milestone payments. Understanding this composition is critical for investors evaluating how GMAB navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Genmab A/S maintains a gross margin of 94.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 44.91%, while the net margin is 39.24%. These profitability ratios, combined with a Return on Equity (ROE) of 28.30%, provide a clear picture of how effectively GMAB converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, GMAB competes directly with industry leaders such as VRTX and PFE. With a market capitalization of $20.43B, it holds a significant position in the sector. When comparing efficiency, GMAB's gross margin of 94.32% stands against VRTX's 86.52% and PFE's 68.76%. Such benchmarking helps identify whether Genmab A/S is trading at a premium or discount relative to its financial performance.
